BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37787304)

  • 41. Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.
    Berhili A; Bensalah M; ElMalki J; Elyagoubi A; Seddik R
    J Med Case Rep; 2021 Oct; 15(1):531. PubMed ID: 34706776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts.
    Rolf N; Liu LYT; Tsang A; Lange PF; Lim CJ; Maxwell CA; Vercauteren SM; Reid GSD
    Cytometry A; 2022 Jan; 101(1):57-71. PubMed ID: 34128309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
    Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. --Immunophenotypic Aberrancies in Acute Leukemia: A Tertiary Care Centre Experience.
    Gupta M; Monga L; Mehrotra D; Chhabra S; Singhal S; Sen R
    Oman Med J; 2021 Jan; 36(1):e218. PubMed ID: 33585041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification.
    De Zen L; Bicciato S; te Kronnie G; Basso G
    Leukemia; 2003 Aug; 17(8):1557-65. PubMed ID: 12886243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Immunophenotypic and Clinical Characteristics of
    Liu SY; Zhu L; Wang CY; He C; Yi SJ; Meng L; Xiao M; Mao X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1639-1646. PubMed ID: 38071040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Iwamoto S; Deguchi T; Ohta H; Kiyokawa N; Tsurusawa M; Yamada T; Takase K; Fujimoto J; Hanada R; Hori H; Horibe K; Komada Y
    Int J Hematol; 2011 Aug; 94(2):185-192. PubMed ID: 21800074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in
    Park SH; You E; Park CJ; Jang S; Cho YU; Yoon CH; Koh KN; Im HJ; Seo JJ
    Ann Lab Med; 2019 Jul; 39(4):358-366. PubMed ID: 30809981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytogenetic aberration in mixed-phenotype acute leukemia in children: A single-center retrospective review.
    Chang TY; Chen SH; Jaing TH; Yang SH; Wen YC; Yang CP; Hung IJ
    Pediatr Neonatol; 2021 Jan; 62(1):21-25. PubMed ID: 32859541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of Immunophenotypic Aberrancies in Adult and Childhood Acute Lymphoblastic Leukemia: Lessons from Regional Variation.
    Rezaei MS; Esfandiari N; Refoua S; Shamaei M
    Iran J Pathol; 2020; 15(1):1-7. PubMed ID: 32095142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity.
    Gajendra S; Anupurba S; Gupta R; Mallick S; Panda D; Thakral D; Gupta SK; Bakhshi S; Seth R; Rai S; Prajapati VK; Singh S
    Int J Lab Hematol; 2023 Aug; 45(4):541-552. PubMed ID: 37078511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Aberrant immunophenotypes in 126 patients with acute leukemia].
    He JJ; Li YH; Sun XJ; Wan SG; Xu J; Su L; Tian D
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1032-6. PubMed ID: 17956685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
    Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
    Czuczman MS; Dodge RK; Stewart CC; Frankel SR; Davey FR; Powell BL; Szatrowski TP; Schiffer CA; Larson RA; Bloomfield CD
    Blood; 1999 Jun; 93(11):3931-9. PubMed ID: 10339502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
    Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
    Kern W; Kohlmann A; Schoch C; Schnittger S; Haferlach T
    Cancer; 2006 Nov; 107(10):2401-7. PubMed ID: 17041886
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.